Maria Matuz1, Ria Benko, Peter Doro, Edit Hajdu, Gyongyver Soos. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szikra u. 8, Hungary, 6725, Szeged, Hungary. matuz@clph.szote.u-szeged.hu
Abstract
OBJECTIVE: To estimate the extent, prevalence, and trends in non-prescription antibiotic use in Hungary between 2000 and 2004 at national and regional levels. To identify determinants of nonprescription antibiotic use. METHOD: Data on non-prescription sales of systemic antibiotics (Anatomical Therapeutic Chemical (ATC) class J01) were analyzed over a five-year period. The 2004 version of the World Health Organisation ATC/defined daily dose (DDD) methodology was used to quantify antibiotic consumption. Non-prescription antibiotic sales were expressed as number of DDD per 1,000 inhabitants per day and as a percentage (%) of total antibiotic use. Further measurement units were introduced for better understanding of consumption and to seek an association between price, prescription antibiotic use, and non-prescription antibiotic use. RESULTS: During the study period nationwide non-prescription sales of antibiotics increased threefold and reached nearly 2% prevalence in 2004. Substantial interregional differences were detected in both the level and the share of non-prescription antibiotics sales. Ten drugs were responsible for 90% of non-prescription antibiotic sales in 2004 (doxycyline, co-amoxiclav, co-trimoxazole, penamecillin, ampicillin, amoxicillin, clindamycin, clarithromycin, norfloxacin, and cefuroxime); of these, doxycycline was the number one nonprescription antibiotic in all five years. A relationship was found between price and non-prescription antibiotic use (R = -0.732, P = 0.016). CONCLUSION: Despite the prescription-only status of antibiotics in Hungary, non-prescription sales occur. A further increase in non-prescription sales of antibiotics could be prevented by strict law enforcement, price augmentation, and intervention focusing on pharmacist and the general public. More detailed studies are needed to identify other sources and causes of self-medication.
OBJECTIVE: To estimate the extent, prevalence, and trends in non-prescription antibiotic use in Hungary between 2000 and 2004 at national and regional levels. To identify determinants of nonprescription antibiotic use. METHOD: Data on non-prescription sales of systemic antibiotics (Anatomical Therapeutic Chemical (ATC) class J01) were analyzed over a five-year period. The 2004 version of the World Health Organisation ATC/defined daily dose (DDD) methodology was used to quantify antibiotic consumption. Non-prescription antibiotic sales were expressed as number of DDD per 1,000 inhabitants per day and as a percentage (%) of total antibiotic use. Further measurement units were introduced for better understanding of consumption and to seek an association between price, prescription antibiotic use, and non-prescription antibiotic use. RESULTS: During the study period nationwide non-prescription sales of antibiotics increased threefold and reached nearly 2% prevalence in 2004. Substantial interregional differences were detected in both the level and the share of non-prescription antibiotics sales. Ten drugs were responsible for 90% of non-prescription antibiotic sales in 2004 (doxycyline, co-amoxiclav, co-trimoxazole, penamecillin, ampicillin, amoxicillin, clindamycin, clarithromycin, norfloxacin, and cefuroxime); of these, doxycycline was the number one nonprescription antibiotic in all five years. A relationship was found between price and non-prescription antibiotic use (R = -0.732, P = 0.016). CONCLUSION: Despite the prescription-only status of antibiotics in Hungary, non-prescription sales occur. A further increase in non-prescription sales of antibiotics could be prevented by strict law enforcement, price augmentation, and intervention focusing on pharmacist and the general public. More detailed studies are needed to identify other sources and causes of self-medication.
Authors: Mark Muscat; Dominique L Monnet; Thomas Klemmensen; Larissa Grigoryan; Maria Hummelshøj Jensen; Morten Andersen; Flora M Haaijer-Ruskamp Journal: Scand J Infect Dis Date: 2006
Authors: Larissa Grigoryan; Johannes G M Burgerhof; Flora M Haaijer-Ruskamp; John E Degener; Reginald Deschepper; Dominique L Monnet; Antonella Di Matteo; Elizabeth A Scicluna; Ana-Claudia Bara; Cecilia Stålsby Lundborg; Joan Birkin Journal: J Antimicrob Chemother Date: 2006-11-22 Impact factor: 5.790
Authors: Stef L A M Bronzwaer; Otto Cars; Udo Buchholz; Sigvard Mölstad; Wim Goettsch; Irene K Veldhuijzen; Jacob L Kool; Marc J W Sprenger; John E Degener Journal: Emerg Infect Dis Date: 2002-03 Impact factor: 6.883
Authors: Larissa Grigoryan; Flora M Haaijer-Ruskamp; Johannes G M Burgerhof; Reli Mechtler; Reginald Deschepper; Arjana Tambic-Andrasevic; Retnosari Andrajati; Dominique L Monnet; Robert Cunney; Antonella Di Matteo; Hana Edelsein; Rolanda Valinteliene; Alaa Alkerwi; Elizabeth Scicluna; Powel Grzesiowski; Ana-Claudia Bara; Thomas Tesar; Milan Cizman; Jose Campos; Cecilia Stålsby Lundborg; Joan Birkin Journal: Emerg Infect Dis Date: 2006-03 Impact factor: 6.883
Authors: Olga Horvat; Vesna Mijatović; Boris Milijasević; Ana Tomas; Milica Paut Kusturica; Zdenko Tomić; Ana Sabo Journal: Front Public Health Date: 2018-03-29
Authors: Miguel Angel Gastelurrutia; Belen Larrañaga; Angel Garay; Francisco de Asís Echeveste; Fernando Fernandez-Llimos Journal: Pharm Pract (Granada) Date: 2013-12-20